These innovative compounds represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose https://safakmmi019072.acidblog.net/70131647/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide